Is it safe to prescribe metformin during the first trimester of pregnancy, and what are the reasons for and against its use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Metformin Use in the First Trimester: Safety and Clinical Considerations

Metformin can be safely given during the first trimester of pregnancy, as it crosses the placenta poorly during this period and does not increase the risk of major congenital malformations. 1

Why Metformin is Safe in the First Trimester

Pharmacokinetic Protection

The key safety feature of first-trimester metformin exposure is poor placental transfer during early pregnancy due to lack of OCT3 cation transporters in the first trimester 1. This creates a natural protective barrier that prevents significant fetal exposure during organogenesis—the critical period for malformation risk.

Evidence on Malformations

  • No increased risk of major birth defects: Multiple studies confirm metformin does not cause congenital malformations when used in the first trimester 2, 3
  • The FDA label states published data "have not reported a clear association with metformin and major birth defects" 2
  • A 2024 study found the risk for live birth with congenital malformations was actually lower with metformin plus insulin (5.7%) versus insulin alone (8.0%), though not statistically significant 4
  • Meta-analysis data suggest a protective effect, with malformation rates of 1.7% in metformin-exposed pregnancies versus 7.2% in disease-matched controls 3

Why You Should Consider Using Metformin in the First Trimester

For Women with PCOS

Continuing metformin through the first trimester in PCOS patients may reduce miscarriage risk and increase live birth rates 5. A 2025 meta-analysis showed:

  • Women who continued metformin throughout the first trimester had possible reduction in miscarriage (OR 0.64) and possible increase in live birth (OR 1.24)
  • Women who stopped metformin once pregnant showed an increase in miscarriage rate (OR 1.46) 5
  • Indirect comparisons consistently favored continuation over discontinuation 5

For Women with Type 2 Diabetes

  • Metformin does not increase risk of nonlive births when continued in early pregnancy 4
  • May help with glycemic control during the critical first trimester when rapid euglycemia is needed
  • Can reduce maternal insulin requirements and gestational weight gain 6, 1

Why You Might Avoid or Discontinue Metformin

Limited Benefit After First Trimester

The 2025 Endocrine Society/European Society of Endocrinology guidelines suggest AGAINST routine addition of metformin to insulin in pregnant individuals with T2DM (Recommendation 4, weak recommendation, very low-quality evidence) 1.

Concerns About Later Pregnancy Exposure

Once past the first trimester, metformin's risk-benefit profile changes:

  • High placental transfer in second/third trimesters: OCT3 transporters become highly expressed, leading to fetal metformin levels equal to or higher than maternal levels 6, 1
  • Concentrated in fetal tissues: Metformin accumulates 1000-fold in fetal and placental mitochondria 1
  • Potential fetal programming effects:
    • Some offspring studies show increased childhood BMI, waist circumference, and adiposity at ages 4-10 years 6, 1
    • Primate studies demonstrate decreased fetal skeletal muscle mass and bioaccumulation in fetal kidney and liver 1
  • Risk of small-for-gestational-age (SGA) infants: Particularly in women with chronic hypertension or nephropathy 1

Specific Populations to Avoid

Do not use metformin in pregnant women with chronic hypertension or nephropathy, as they are at highest risk for SGA and fetal growth restriction 1.

Clinical Algorithm for First Trimester Metformin Use

Women Already on Metformin Pre-Pregnancy

PCOS patients:

  • Continue metformin through at least the end of first trimester at effective doses (1000-2000 mg/day) 5, 7
  • May reduce miscarriage risk by 56% compared to stopping at conception 5
  • Consider continuing to end of first trimester or beyond based on individual risk-benefit

Type 2 Diabetes patients:

  • Can safely continue through first trimester if already on metformin 4
  • Consider stopping at end of first trimester (12-13 weeks) when placental OCT3 transporters become highly expressed 1
  • Transition to insulin as primary therapy for second/third trimesters 1

Women Not on Metformin Pre-Pregnancy

Do not routinely initiate metformin in first trimester for:

  • Type 2 diabetes (insulin is preferred) 1
  • Prevention of gestational diabetes (no proven benefit) 6

May consider initiating for:

  • PCOS with recurrent miscarriage history (though evidence is stronger for pre-conception initiation) 5

Key Pitfalls to Avoid

  1. Don't assume metformin is safe throughout pregnancy: The first trimester safety profile does NOT extend to later pregnancy due to dramatically increased placental transfer 1

  2. Don't use metformin as monotherapy for T2DM in pregnancy: Most women with T2DM require insulin to achieve glycemic targets; metformin is not a substitute 1

  3. Don't continue metformin in women with hypertension/nephropathy: This subgroup has highest SGA risk 1

  4. Don't forget the timing matters: The protective effect of poor placental crossing is specific to the first trimester 1

Summary Statement

For women already taking metformin who become pregnant, continuation through the first trimester is safe and may be beneficial, particularly for PCOS patients where it may reduce miscarriage risk. The drug crosses the placenta poorly during this period and does not cause birth defects 1, 2. However, consider discontinuing at the end of the first trimester (around 12-13 weeks) when placental transporters develop and fetal exposure increases dramatically 1. For women with T2DM, insulin should be the primary therapy, with metformin playing at most an adjunctive role 1.

References

Related Questions

Can metformin extended-release (ER) be used during pregnancy?
What is the appropriate metformin dosage for a pregnant patient, both if she was already taking it before pregnancy and if she is starting it now?
Is it safe for a pregnant woman with Polycystic Ovary Syndrome (PCOS) and metabolic features taking metformin (Glucophage) 500 mg twice daily to continue the medication up to 12 weeks of gestation and then stop abruptly?
Should metformin be continued during the first trimester of pregnancy for a woman with pre‑gestational diabetes or polycystic ovary syndrome?
What is the recommended follow-up schedule after starting metformin (Metformin Hydrochloride) for Polycystic Ovary Syndrome (PCOS)?
In a pediatric patient with ankle and knee pain, limited range of motion, joint warmth and effusion, who is vitally stable, afebrile, and had gastroenteritis two weeks ago, what is the appropriate management (e.g., oral ibuprofen, aspirin, additional analgesia, or synovial fluid aspiration for analysis and culture)?
In a pregnant patient with a random glucose of 280 mg/dL, what oral glucose‑lowering medications are appropriate?
What are the typical symptoms and recommended treatment options for a pharyngoesophageal (Zenker's) diverticulum?
Does diabetic retinopathy worsen with continued semaglutide (Ozempic) therapy?
How should a patient presenting with insomnia, auditory hallucinations, homicidal ideation, a history of substance use, and a dysfunctional family be managed acutely?
Should I consult an otolaryngologist (ENT) or a gastroenterologist (GI) for evaluation and management of a pharyngoesophageal diverticulum?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.